Related Experiment Video
Updated: Jul 15, 2026
The Nematode Caenorhabditis Elegans - A Versatile In Vivo Model to Study Host-microbe Interactions
Published on: October 18, 2017
In Vivo Effect of Halicin on Methicillin-Resistant Staphylococcus aureus-Infected Caenorhabditis elegans and Its
Li-Ting Kao1,2, Tsung-Ying Yang3,4, Wei-Chun Hung5
1Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Abstract:
Recently, the high proportion of methicillin-resistant Staphylococcus aureus infections worldwide has highlighted the urgent need for novel antibiotics to combat this crisis. The recent progress in computational techniques for use in health and medicine, especially artificial intelligence (AI), has created new and potential approaches to combat antibiotic-resistant bacteria, such as repurposing existing drugs, optimizing current agents, and designing novel compounds. Halicin was previously used as a diabetic medication, acting as a c-Jun N-terminal protein kinase (JNK) inhibitor, and has recently demonstrated unexpected antibacterial activity. Although previous efforts have highlighted halicin's potential as a promising antibiotic, evidence regarding its effectiveness against clinical strains remains limited, with insufficient proof of its clinical applicability. In this study, we sought to investigate the antibacterial activity of halicin against MRSA clinical strains to validate its clinical applicability, and a C. elegans model infected by MRSA was employed to evaluate the in vivo effect of halicin against MRSA. Our findings revealed the antibacterial activity of halicin against methicillin-resistant S. aureus clinical strains with MICs ranging from 2 to 4 µg/mL. Our study is also the first work to evaluate the in vivo effect of halicin against S. aureus using a C. elegans model, supporting its further development as an antibiotic.
Insights
Halicin shows promise in fighting antibiotic-resistant infections. This study confirms its effectiveness against methicillin-resistant Staphylococcus aureus (MRSA) clinical strains and demonstrates its potential in a C. elegans model, supporting its development as a novel antibiotic.
Area of Science:
- Infectious Diseases
- Pharmacology
- Computational Biology
Background:
- The rise of antibiotic-resistant bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA), necessitates the development of new antimicrobial agents.
- Artificial intelligence (AI) offers novel strategies for drug discovery, including repurposing existing medications.
- Halicin, a former diabetic drug, has shown potential antibacterial activity but requires further validation against clinical strains.
Purpose of the Study:
- To investigate the antibacterial activity of Halicin against clinical strains of MRSA.
- To evaluate the in vivo efficacy of Halicin in a C. elegans model infected with MRSA.
- To assess the clinical applicability of Halicin as a potential antibiotic.
Main Methods:
- Determined the Minimum Inhibitory Concentrations (MICs) of Halicin against MRSA clinical isolates.
- Utilized a C. elegans infection model to assess the in vivo antibacterial effects of Halicin against MRSA.
- Evaluated Halicin's potential for clinical application based on experimental findings.
Main Results:
- Halicin demonstrated significant antibacterial activity against MRSA clinical strains, with MICs ranging from 2 to 4 µg/mL.
- The study is the first to report the in vivo efficacy of Halicin against MRSA using a C. elegans model.
- Results support Halicin's potential as a viable therapeutic option against MRSA infections.
Conclusions:
- Halicin exhibits potent antibacterial activity against clinically relevant MRSA strains.
- In vivo studies in C. elegans confirm Halicin's effectiveness in an infection model.
- Halicin warrants further investigation and development as a novel antibiotic to combat MRSA.
